

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

HB 2002 - SB 2099

February 7, 2018

SUMMARY OF BILL: Allows the direct administration of buprenorphine mono or buprenorphine without use of naloxone by a healthcare provider for the treatment of substance use disorder prescribed by a physician under certain circumstances.

ESTIMATED FISCAL IMPACT:

NOT SIGNIFICANT

Assumptions:

- Based on information provided by the Department of Health (DOH), the proposed legislation will not have a significant impact on the procedures and processes of the health related boards, the Board of Pharmacy, or the DOH.
- Pursuant to Tenn. Code Ann. § 4-29-121, all health related boards are required to be self-supporting over a two-year period. The Board of Medical Examiners had a surplus of \$382,952 in FY16-17, a deficit of \$4,714 in FY16-17, and a cumulative reserve balance of \$2,855,288 on June 30, 2017.
- The Board of Osteopathic Physicians had a surplus of \$102,565 in FY15-16, a surplus of \$91,306 in FY16-17, and a cumulative reserve balance of \$794,231 on June 30, 2017.
- The Board of Pharmacy had a surplus of \$885,058 in FY15-16, a surplus of \$620,117 in FY16-17, and a cumulative reserve balance of \$2,601,038 on June 30, 2017.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in blue ink that reads "Krista M. Lee".

Krista M. Lee, Executive Director

/jem

HB 2002 - SB 2099